EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Suzetrigine: A novel selective sodium channel inhibitor for pain

Denise Courtney, Sudheer Potru, Paige Mathew

American Journal of Health-System Pharmacy · 09.03.2026 · 83 (6) · 245-253

DOI: 10.1093/ajhp/zxaf219 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 18.08.2025. Verfasst von Denise Courtney und 2 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Health Administration Southeast Network, Decatur, GA, USA. Hauptthemen laut MEDLINE: Sodium Channel Blockers, Voltage-Gated Sodium Channel Blockers, Pain. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To explore suzetrigine, a novel voltage-gated sodium channel inhibitor for pain management. Summary Suzetrigine is a first-in-class, oral peripheral sodium channel inhibitor that selectively targets Nav1.8 channels and was recently approved for the treatment of moderate to severe acute pain. In phase 3 trials, suzetrigine demonstrated superior efficacy to placebo in reducing pain intensity after surgery and was generally well tolerated. Studies for nonacute pain indications, including diabetic peripheral neuropathy and painful lumbosacral radiculopathy, are in progress.

Conclusion

Suzetrigine represents an advancement in pain management as a nonopioid alternative for pain with potentially lower abuse risk and potentially fewer serious adverse effects when compared to opioids. While initial results are promising, further research is needed to establish its long-term safety and efficacy for various painful conditions. Research will continue in the area of analgesics that selectivity inhibit peripheral sodium channels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium Channel BlockersVoltage-Gated Sodium Channel BlockersPainHumansAnimalsSpiro CompoundsThiophenes

Stichwörter der Autor:innen

acute painanalgesicpainvoltage-gated sodium channels

Substanzen

Sodium Channel BlockersVoltage-Gated Sodium Channel Blockers((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amineSpiro CompoundsThiophenes

Autor:innen und Institutionen

  • Veterans Health Administration Southeast Network, Decatur, GA, USA.
  • Atlanta VA Health Care System, Decatur, GA, USA.
  • VA Capitol Health Care Network, Washington, DC, USA.

Zitieren

APA

Courtney, D., Potru, S., & Mathew, P. (2026). Suzetrigine: A novel selective sodium channel inhibitor for pain. American Journal of Health-System Pharmacy, 83(6), 245-253. https://doi.org/10.1093/ajhp/zxaf219

Vancouver

Courtney D, Potru S, Mathew P. Suzetrigine: A novel selective sodium channel inhibitor for pain. American Journal of Health-System Pharmacy. 2026;83(6):245-253. doi:10.1093/ajhp/zxaf219

BibTeX
@article{Courtney2026,
  author = {Courtney, Denise and Potru, Sudheer and Mathew, Paige},
  title = {Suzetrigine: A novel selective sodium channel inhibitor for pain},
  journal = {American Journal of Health-System Pharmacy},
  year = {2026},
  volume = {83},
  number = {6},
  pages = {245--253},
  doi = {10.1093/ajhp/zxaf219}
}
Kostenlos starten →